Clinical Trials Browser

Phase 2/3 × Cholangiocarcinoma × Neoadjuvant Therapy × Clear all

NCT04669496 2025-09-04

Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Phase 2/3 Active not recruiting

Gastrointestinal

Cholangiocarcinoma